<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055002</url>
  </required_header>
  <id_info>
    <org_study_id>QP09C08</org_study_id>
    <nct_id>NCT01055002</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers</brief_title>
  <official_title>A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queensland Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Pharm Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trident Clinical Research Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of a protocol for inducing a falciparum malaria infection in healthy&#xD;
      volunteers in order to test the activity of novel agents being developed as drugs for the&#xD;
      treatment of uncomplicated malaria. In this pilot study, 16 healthy male volunteers will be&#xD;
      administered a low level malaria infection via infected human red blood cells. After 6 days&#xD;
      they will be administered one of two registered antimalarial treatments (8 volunteers for&#xD;
      each treatment) in order to define the rate of clearance of the infection. This information&#xD;
      will be used to design similar future studies for the initial assessment of the efficacy of&#xD;
      novel antimalarial drugs in development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, controlled, randomized, study using a BSP inoculum challenge as a&#xD;
      model to assess the activity of antimalarial agents. The study will be conducted in 2 cohorts&#xD;
      (n = 6 and n = 10). Cohort 2 will not commence until at least after day 12 of cohort 1 and&#xD;
      review by Safety Review Team following day 9 exit of cohort 1. The participants will be&#xD;
      randomized 1:1 to the two registered antimalarials. This is an enabling study using&#xD;
      registered antimalarial drugs as reference treatments (one slow acting and one fast acting),&#xD;
      aimed to inform trial design, endpoints and testing regimens for assessing new candidate&#xD;
      antimalarial drugs in development. The study will follow the sequence of the challenge&#xD;
      inoculation, reference treatment and follow-up.&#xD;
&#xD;
      Healthy male participants will be inoculated on Day 1 with ~1,800 Plasmodium&#xD;
      falciparum-infected human erythrocytes administered intravenously. On an outpatient basis,&#xD;
      participants will be monitored morning (AM) and night (PM) from day 3 to day 5 for adverse&#xD;
      events and the unexpected early onset of symptoms, signs or parasitological evidence of&#xD;
      malaria. On day 5 evening, participants will be admitted to the study unit and confined for&#xD;
      safety monitoring and antimalarial treatment. Reference treatment administration will begin&#xD;
      on the evening of Day 6 and continued on Day 7 and 8 (3 days of treatment).&#xD;
&#xD;
      If clinical or parasitologic evidence of malaria (either the identification of two or more&#xD;
      malaria parasites on a malaria thick film, platelet count less than 100 x109/L, or the onset&#xD;
      of clinical features of malaria) occurs before day 6 evening, allocated treatment will begin&#xD;
      at this time.&#xD;
&#xD;
      Following treatment, participants will be followed up as inpatients for at least 86 hours, (4&#xD;
      evenings) to ensure tolerance of the therapy and clinical response, then if clinically well&#xD;
      on an outpatient basis for safety and continued presence of malaria parasites via PCR and&#xD;
      thick blood film review.&#xD;
&#xD;
      Adverse events will be monitored via telephone monitoring, within the clinical research unit&#xD;
      and on outpatient review after malaria challenge inoculation and antimalarial study drug&#xD;
      administration. Blood samples for safety evaluation, malaria monitoring, and red blood cell&#xD;
      antibodies will be drawn at baseline and at nominated times after malaria challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasite clearance rates by PCR</measure>
    <time_frame>1-7 days after drug treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite growth rates by PCR</measure>
    <time_frame>1-6 days after inoculation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <condition>Non-smokers</condition>
  <arm_group>
    <arm_group_label>Artemether/lumefantrine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atovaquone/Proguanil HCl tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood stage parasite (BSP) inoculum</intervention_name>
    <description>Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1</description>
    <arm_group_label>Artemether/lumefantrine tablets</arm_group_label>
    <arm_group_label>Atovaquone/Proguanil HCl tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged 18-45 years who do not live alone&#xD;
&#xD;
          -  BMI within 18-30&#xD;
&#xD;
          -  Understand the procedures and risks involved&#xD;
&#xD;
          -  Contactable for the duration of the study&#xD;
&#xD;
          -  Non-smokers and in good health&#xD;
&#xD;
          -  Good venous access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malaria&#xD;
&#xD;
          -  Been in a malaria-endemic country within 12 months&#xD;
&#xD;
          -  Evidence of cardiovascular risk&#xD;
&#xD;
          -  Splenectomy&#xD;
&#xD;
          -  History of severe allergic reactions after vaccination of infusion&#xD;
&#xD;
          -  Any serious chronic illness&#xD;
&#xD;
          -  Inherited genetic anomaly&#xD;
&#xD;
          -  Any volunteers wishing to donate blood to the blood bank in the future&#xD;
&#xD;
          -  Retinal or visual field changes&#xD;
&#xD;
          -  Diagnosis of chronic severe psychiatric condition&#xD;
&#xD;
          -  Hospitalisation within 5 years for psychiatric illness, suicide attempt or danger to&#xD;
             self or others&#xD;
&#xD;
          -  Receiving psychiatric drugs (some exceptions)&#xD;
&#xD;
          -  Known QTc prolongation&#xD;
&#xD;
          -  Family history of cardiac anomalies&#xD;
&#xD;
          -  Recent or current therapy with an antibiotic or drug with potential antimalarial&#xD;
             activity&#xD;
&#xD;
          -  Known hypersensitivity to artemether or lumefantrine, atovaquone or proguanil&#xD;
             hydrochloride or any of the excipients&#xD;
&#xD;
          -  Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 OR&#xD;
             drugs that are known to prolong the QTc interval&#xD;
&#xD;
          -  Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or&#xD;
             anticoagulants. Currently receiving or have previously received immunosuppressive&#xD;
             therapy, including systemic steroids including ACTH or inhaled steroids in dosages&#xD;
             which are associated with hypothalamicpituitary- adrenal axis suppression such as&#xD;
             1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency&#xD;
             corticosteroids&#xD;
&#xD;
          -  Presence of acute infectious disease or fever&#xD;
&#xD;
          -  Evidence of acute illness within the four weeks before trial prior to screening&#xD;
&#xD;
          -  Significant intercurrent disease of any type, in particular liver, renal, cardiac,&#xD;
             pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical&#xD;
             examination, and/or laboratory studies including urinalysis&#xD;
&#xD;
          -  Alcohol consumption greater than community norms&#xD;
&#xD;
          -  A history of drug habituation, or any prior intravenous usage of an illicit substance&#xD;
&#xD;
          -  Medical requirement for intravenous immunoglobulin or blood transfusions&#xD;
&#xD;
          -  Participation in any investigational product study within the 8 weeks preceding the&#xD;
             study&#xD;
&#xD;
          -  Participation in any research study involving significant blood sampling, or blood&#xD;
             donation to a blood bank during the 8 weeks preceding the study&#xD;
&#xD;
          -  Have ever received a blood transfusion&#xD;
&#xD;
          -  Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I &amp;&#xD;
             II (HTLVI &amp; HTLVII), and syphilis&#xD;
&#xD;
          -  Any clinically significant biochemical or haematologic abnormality (Hb must be&#xD;
             â‰¥13.5g/dL)&#xD;
&#xD;
          -  Ingestion of any poppy seeds within the 48 hours prior to the screening blood test&#xD;
&#xD;
          -  Detection of any recreational drug listed in the urine drug screen&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarthy, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queensland Institute of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Clinics, Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr James McCarthy</name_title>
    <organization>Queensland Institute of Medical Research</organization>
  </responsible_party>
  <keyword>Health male volunteers</keyword>
  <keyword>Male volunteers aged 18-45 years</keyword>
  <keyword>Non-smokers and in good health</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

